Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results.(Financial report)
Blood Weekly; 11/19/2009; 2211 words; ...see also Alnylam Pharmaceuticals, Inc.). "Activities...Officer of Alnylam. "We are...biotech and pharmaceutical partners...2009, Alnylam had cash...with Takeda Pharmaceutical Company Limited...Cubist Pharmaceuticals, Inc., Biogen...

Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society OTS Meeting.
AIDS Weekly; 11/16/2009; 1637 words; Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi...molecules that mediate RNAi. In addition, Alnylam scientists and collaborators presented...see also Alnylam Pharmaceuticals, Inc.). "Delivery of siRNAs remains one...

Alnylam to Participate in Major Cardiovascular Disease Research Grant Awarded to Scientists at University of Pennsylvania.
Heart Disease Weekly; 11/15/2009; 1371 words; ...Cardiology, Genetics, Pharmaceutical, Research, Science, Alnylam Pharmaceuticals Inc., Cardiology, Cardiovascular...Myocardial Infarction, Pharmaceutical Business, Pharmaceutical...Therapy, Treatment, Alnylam Pharmaceuticals Inc. This article was...

Tekmira Pharmaceuticals Corporation Announces Third Quarter 2009 Operating Results and Provides Corporate Update.(Financial report)
Marketwire Canada; 11/12/2009; 3429 words; ...Tekmira Pharmaceuticals Corporation...revenue from our pharmaceutical partners who are...Additionally, both Alnylam Pharmaceuticals and Roche are...partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY...

Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day.
Business Wire; 11/12/2009; 2382 words; ...Opportunity - CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading...being held in New York today. Alnylam scientists and management will...mediated amyloidosis (ATTR). Alnylam is developing RNAi therapeutics...